电邮这篇文章 Use of the medicine Alphagan®P in the treatment of paediatric glaucoma
- 作者: Katargina L.1, Mazanova E.1
-
隶属关系:
- The Helmholtz Moscow Research Institute of Eye Diseases
- 期: 卷 9, 编号 3 (2014)
- 页面: 10-13
- 栏目: Articles
- URL: https://journals.rcsi.science/1993-1859/article/view/37588
- DOI: https://doi.org/10.17816/rpoj37588
- ID: 37588
如何引用文章
全文:
详细
The article presents the experience of one of the modern anti-hypertensive medicine, approved for use in children, Alphagan® P in various forms, stages of congenital and secondary glaucoma in children. Data obtained in this study allowed us to estimate the effectiveness of the drug as monotherapy and in combined appointment, a comparative analysis of the degree of IOP reduction at different stages and forms of paediatric glaucoma, including young children.
作者简介
Ljudmila Katargina
The Helmholtz Moscow Research Institute of Eye Diseases
Email: katargina@igb.ru
д.м.н., профессор, заместитель директора по научной работе 105062, Moscow, Russia
Ekaterina Mazanova
The Helmholtz Moscow Research Institute of Eye Diseases
Email: dho@igb.ru
к.м.н., научный сотрудник отдела патологии глаз у детей 105062, Moscow, Russia
参考
- Аветисов Э.С., Ковалевский Е.И., Хватова А.В. Руководство по детской офтальмологию. М.: Медицина; 1987.
- Moore W., Nischal K.K. Pharmacologic management of glaucoma in childhood. Paediatr. Drugs. 2007; 9(2): 71-9.
- Coppens G., Stalmans I., Zeyen T., Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J. Pediatr. Ophthalmol. Strabismus. 2009. 46(1): 12-8.
- Daubert G.P. Is brimonidine ophthalmic a safe therapy for infants? J. Clin. Pharmacol. Ther 2006; 31(3): 289-92.
- Montero-de-Espinosa I., Marquez-de-Aracena R., Morales C. Ocular hypertension in children treated with brimonidine 0,2%. A clinical study. Arch. Soc. Esp. Oftalmol. 2006; 81(3): 155-9.
- Bowman R.J., Cope J., Nischal K.K. Ocular and systemic side effects of brimonidine 0,2% eye drops (Alphagan) in children. Eye (Lond). 2004; 18(1): 24-6.
